Barclays Upgrades Momenta Pharmaceuticals (MNTA) to Overweight
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Barclays upgraded Momenta Pharmaceuticals (NASDAQ: MNTA) from Equalweight to Overweight with a price target of $19.00 (from $13.00).
Shares of Momenta Pharmaceuticals closed at $11.77 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Stifel Upgrades Legacy Reserves (LGCY) to Hold
- UPDATE: MKM Partners Upgrades Masco (MAS) to Buy
- TD Ameritrade (AMTD) to Acquire Scottrade in $4B Cash & Stock Deal
Create E-mail Alert Related CategoriesHot Upgrades, Upgrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!